Asparagine deamidation dependence on buffer type, pH, and temperature

Journal of Pharmaceutical Sciences

Volumn 102, Issue 6, 2013, Pages 1712-1723

  Pace, Amanda L ^a   Wong, Rita L ^a   Zhang, Yonghua Taylor ^a   Kao, Yung Hsiang ^a   Wang, Y John ^a  

^a GENENTECH INC   (United States)

Author keywords

Buffer; Deamidation; Formulation; Kinetics; PH; Protein formulation; Stability; Temperature

Indexed keywords

ASPARAGINE; BUFFER; HYDROXIDE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ARTICLE; CONCENTRATION (PARAMETERS); DEAMINATION; ION EXCHANGE CHROMATOGRAPHY; KINETICS; PH; ROOM TEMPERATURE; SHELF LIFE; TEMPERATURE;

EID: 84877926248     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23529     Document Type: Article

References (28)

1. Wakankar A, Borchardt R. 2006. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci 95:2321-2336.
2. Chelius D, Rehder DS, Bondarenko PV. 2005. Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. Anal Chem 77:6004-6011.
3. Patel K, Borchardt RT. 1990. Chemical pathways of peptide degradation. III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides. Pharm Res 7:787-793.
4. Capasso S, Mazzarella L, Sica F, Zagari A, Salvadori S. 1993. Kinetics and mechanism of succinimide ring formation in the deamidation process of asparagine residues. J Chem Soc Perkin Trans 2 2:679-682.
5. Geiger T, Clarke S. 1987. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. J Biol Chem 262:785-794.
6. Peters B, Trout BL. 2006. Asparagine deamidation: pH-dependent mechanism from density functional theory. Biochemistry 45:5384-5392.
7. Bewley T, Pearlman R. 1993. Stability and characterization of human growth hormone. Pharm Biotechnol 5:1-58.
8. Senderoff RI, Wootton SC, Boctor AM, Chen TM, Giordani AB, Julian TN, Radebaugh GW. 1994. Aqueous stability of human epidermal growth factor 1-48. Pharm Res 11:1712-1720.
9. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. 2008. Heterogeneity of monoclonal antibodies. J Pharm Sci 97:2426-2244.
10. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. 2001. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B 752:233-245.
11. Yan B, Steen S, Hambly D, Valliere-Douglass J, Bos TV, Smallwood S, Yates Z, Arroll T, Han Y, Gadgil H, Latypov RF, Wallace A, Lim A, Kleemann GR, Wang W, Balland A. 2009. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci 98:3509-3521.
12. Karpusas M, Lucci J, Ferrant J, Benjamin C, Taylor FR, Strauch K, Garber E, Hsu Y-M. 2001. Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody. Structure 9:321-329.
13. Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, Klinguer-Hamour C, Kirchmeier M, Corvaia N, Ionescu R, Beck A. 2009. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem 392:145-154.
14. Liu H, Gaza-Bulseco G, Sun J. 2006. Characterization of the stability of a fully human monoclonal IgG after prolonged incubation and elevated temperature. J Chromatogr B 837:35-43.
15. Sinha S, Zhang L, Duan S, Williams TD, Vlasak J, Ionescu R, Topp EM. 2009. Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody. Protein Sci 18:1573-1584.
16. Kosky AA, Razzaq UO, Treuheit MJ, Brems DN. 1999. The effects of alpha-helix on the stability of Asn residues: Deamidation rates in peptides of varying helicity. Protein Sci 8:2519-2523.
17. Wearne SJ, Creighton TE. 1989. Effect of protein conformation on rate of deamidation: Ribonuclease A. Proteins 5:8-12.
18. Gaza-Bulseco G, Li B, Bulseco A, Liu H. 2008. Method to differentiate Asn deamidation that occurred prior to and during sample preparation of a monoclonal antibody. Anal Chem 24:9491-9498.
19. Teshima G, Stults JT, Ling V, Canova-Davis E. 1991. Isolation and characterization of a succinimide variant of methionyl human growth hormone. J Biol Chem 266:13544-13547.
20. Moorhouse KG, Nashabeh W, Deveney J, Bjork NS, Mulkerrin MG, Ryskamp T. 1997. Validation of an HPLC method for the analysis of the charge heterogeneity of the recombinant monoclonal antibody IDEC-C2B8 after papain digestion. J Pharm Biomed Anal 16:593-603.
21. Ionescu R, Vlasak J. 2010. Kinetics of chemical degradation in monoclonal antibodies: Relationship between rates at the molecular and peptide levels. Anal Chem 82:3198-3206.
22. Li B, Gorman EM, Moore KD, Williams T, Schowen RL, Topp EM, Borchardt RT. 2004. Effects of acidic N+1 residues on asparagine deamidation rates in solution and in the solid state. J Pharm Sci 94:666-675.
23. Gokarn YR, Kras E, Nodgaard C, Dharmavaram V, Fesinmeyer RM, Hultgen H, Brych S, Remmele RL, Brems DN, Hershenson S. 2008. Self-buffering antibody formulations. J Pharm Sci 97:3051-3066.
24. Goldberg RN, Kishore N, Lennen RM. 2002. Thermodynamic quantities for the ionization reactions of buffers. J Phys Chem 31:231-363.
25. Vanderzee CE, Swanson JA. 1963. Heats of dilution and relative apparent molal enthalpies of aqueous sodium perchlorate and perchloric acid. J Phys Chem 67:285-291.
26. Shire SJ. 1996. Development of rhDNase I. Formulation, characterization, and stability of protein drugs. New York: Plenum Press, pp 414-417.
27. Stratton LP, Kelly RM, Rowe J, Shively JE, Smith DD, Carpenter JF, Manning MC. 2001. Controlling deamidation rates in a model peptide: Effects of temperature, peptide concentration, and additives. J Pharm Sci 90:2141-2148.
28. Kommanaboyina B, Rhodes CT. 1999. Trends in stability testing, with emphasis on stability during distribution and storage. Drug Dev Ind Pharm 25(7):857-868.